Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses (2011 - 2026)

Acadia Pharmaceuticals' Other Accumulated Expenses history runs 16 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 72.49% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (up 72.49% YoY), while the FY2025 annual figure was $5.9 million, up 73.78% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $16.1 million, up from $5.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $16.1 million in Q1 2026, with the low at $986000.0 in Q2 2022.
• The 5-year median for Other Accumulated Expenses is $8.9 million (2024), against an average of $7.8 million.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 777.84% in 2023, then tumbled 69.31% in 2024.
• Acadia Pharmaceuticals' Other Accumulated Expenses stood at $2.7 million in 2022, then soared by 307.53% to $11.0 million in 2023, then slumped by 69.31% to $3.4 million in 2024, then surged by 73.78% to $5.9 million in 2025, then soared by 173.92% to $16.1 million in 2026.
• Business Quant data shows ACAD's Other Accumulated Expenses at $16.1 million in Q1 2026, $5.9 million in Q4 2025, and $5.0 million in Q3 2025.